Archive · 2 Jun 2025
Glenmark Pharma's Cancer Drug Shows Promise for Myeloma
Imagine your body has a type of cancer called multiple myeloma, which affects your blood.
Scientists have been working on a new medicine called ISB 2001 to help fight it.
In a study, this medicine showed good results, shrinking the cancer in many patients.
The medicine targets cancer cells and helps the body's immune system fight the disease.
Most patients didn't have serious problems from the medicine.
Doctors are still figuring out the best way to use it, but it looks like a promising new option for people with this type of cancer, especially those who haven't found success with other treatments.
IGI's new drug, ISB 2001, showed positive results in early-stage trials for multiple myeloma.
The study included 35 patients with relapsed or refractory multiple myeloma.
The drug achieved a 79% overall response rate in patients.
Side effects were manageable, and no patients stopped treatment due to safety concerns.
The FDA has granted ISB 2001 fast track status.
- Who
- Ichnos Glenmark Innovation (IGI) developed the drug, ISB 2001.
- What
- An early-stage study of a new cancer drug for multiple myeloma showed promising results.
- When
- Results were shared at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025.
- Where
- The study was conducted globally, with sites in the US and Australia.
- Why
- To find an effective treatment for relapsed or refractory multiple myeloma, a blood cancer with limited treatment options.
- Drug Name
- ISB 2001
- Disease
- Relapsed or refractory multiple myeloma
- Overall Response Rate
- 79%
- Complete Response
- One in three patients
- Trial Name
- TRIgnite-1
- Patients Treated
- 35
- FDA Status
- Fast track